NCT03484819 2025-03-03Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell LymphomaNational Cancer Institute (NCI)Phase 2 Completed12 enrolled 13 charts